[go: up one dir, main page]

US20060177516A1 - Food-supplement composition suitable for promoting iron absorption - Google Patents

Food-supplement composition suitable for promoting iron absorption Download PDF

Info

Publication number
US20060177516A1
US20060177516A1 US10/546,247 US54624705A US2006177516A1 US 20060177516 A1 US20060177516 A1 US 20060177516A1 US 54624705 A US54624705 A US 54624705A US 2006177516 A1 US2006177516 A1 US 2006177516A1
Authority
US
United States
Prior art keywords
iron
composition
cartilage
extract
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/546,247
Inventor
Gianfranco Merizzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medestea Research and Production SpA
Original Assignee
Medestea Research and Production SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Research and Production SpA filed Critical Medestea Research and Production SpA
Assigned to MEDESTEA RESERACH AND PRODUCTION S.R.L. reassignment MEDESTEA RESERACH AND PRODUCTION S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MERIZZI, GIANFRANCO
Publication of US20060177516A1 publication Critical patent/US20060177516A1/en
Priority to US12/034,046 priority Critical patent/US8119167B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Definitions

  • the present invention relates to a food-supplement or pharmaceutical composition suitable for promoting iron absorption and to the treatment of anaemia conditions caused by lack of iron.
  • the main problem is due to the low rate of iron absorption by the organism, which is of the order of approximately only 5-15% of the iron administered.
  • research relating to anti-anaemic agents for the treatment of anaemia caused by iron deficiency have been directed mainly towards the identification of preparations which can improve the solubility of iron with the use of pharmaceutical additives which improve its solubility by forming complex salts with iron, and agents such as reducing agents which can prevent oxidation of ferrous iron to ferric iron.
  • the present invention is based on the discovery of the fact that iron absorption can be increased by the administration of a composition comprising cartilage and absorbable zinc.
  • the subject of the invention is therefore the use of a composition comprising cartilage and absorbable zinc for the preparation of a food supplement or a drug which is suitable for increasing iron absorption in an individual suffering from a lack of that element and is suitable for the treatment of anaemia conditions caused by lack of iron.
  • composition has been found suitable for promoting the absorption both of iron which is naturally present in foods and of iron which is administered—generally as a ferrous salt or complex—as a supplement in diets that are poor in iron or as a drug in the treatment of anaemia caused by lack of iron.
  • the cartilage which is used within the scope of the invention is generally an extract of fish cartilage, in particular cartilage of sharks or other large fish such as rays, comprising—as active ingredient—chondroitin sulphate, that is, a mixture of acid mucopolysaccharides formed by a repeating linear unit containing several sulphate groups.
  • the basic units are constituted by N-acetyl-galactosamine and by glucuronic acid.
  • Standardized extracts of shark cartilage are available commercially and their anti-angiogenic, anti-tumour, and anti-inflammatory activity and activity in improving skin and cartilage nutrition are already known.
  • the absorbable zinc is present in the composition in the form of salts with various counter-ions such as, for example, citrate, aspartate, pidolate, orotate, fumarate, gluconate, lactate, malate, succinate, picolinate, ⁇ -ketoglutarate, or mixtures thereof.
  • various counter-ions such as, for example, citrate, aspartate, pidolate, orotate, fumarate, gluconate, lactate, malate, succinate, picolinate, ⁇ -ketoglutarate, or mixtures thereof.
  • a form of zinc administration may be so-called Krebs zinc which is constituted by salified zinc with a mixture of anions formed by five primary organic acids of the Krebs cycle, that is, a mixture of zinc salts of citric, fumaric, malic, ⁇ -ketoglutaric, and succinic acids.
  • the cartilage extract. and the zinc may be administered, according to the invention, within the following range of dosages:
  • cartilage extract 10-2000 mg/day
  • composition may also comprise a haematopoietic agent with anti-anaemic properties such as, in particular, folic acid, cyanocobalamin (vitamin B 12 ) and pyridoxine (vitamin B 6 ) and mixtures thereof with daily doses of the order of from 60 to 2000 ⁇ g/day.
  • a haematopoietic agent with anti-anaemic properties such as, in particular, folic acid, cyanocobalamin (vitamin B 12 ) and pyridoxine (vitamin B 6 ) and mixtures thereof with daily doses of the order of from 60 to 2000 ⁇ g/day.
  • the composition also comprises at least one anti-oxidizing agent or preferably a mixture of antioxidants which preferably comprise hydrophilic antioxidants and hydrophobic antioxidants.
  • anti-oxidizing agents comprise:
  • vitamin C typically administered in quantities of from 50 to 1000 mg/day,
  • vitamin E typically administered in quantities of from 5 to 500 mg/day, and
  • bioflavonoids containing proanthocyanidin and terpene compounds.
  • the preferred sources of bioflavonoids or of terpene compounds in the composition of the invention comprise natural extracts such as, in particular:
  • extract of Vitis vinifera (containing leucocyanidin or leucoanthocyanin), comprising procyanidolic oligomers, typically dimers, trimers, tetramers, pentamers and heptamers produced by condensation of monomeric units of flavan-3-ols and flavan-3,4-diols, free or esterified with gallic acid;
  • Centella asiatica obtained by extraction and purification of the aerial part of Centella asiatica (asiatic hydrocotyl), typically comprising a terpenic mixture of madecassic acid (about 30%), asiatic acid (about 30%) and asiaticoside (about 40%);
  • the above-mentioned extracts may be used in association in the composition according to the invention and may optionally be standardized extracts in complexed form with phospholipids to improve bio-availability.
  • Typical dosages of these extracts in the composition of the invention are of the order of from 10 to 500 mg/day.
  • the invention includes within its scope both iron-free compositions and compositions including iron—generally as ferrous ion—the combined use of which is rendered necessary when the lack of iron in the patient undergoing treatment is also due to a diet that is poor in iron. It is intended that the administration of iron supplements may be performed in association with the composition according to the invention or in combined treatment.
  • the composition may typically comprise doses of the order of from 5 to 300 mg/day of iron, as the ferrous ion, for example, as ferrous sulphate or other salts such as, in particular, aspartate, citrate, picolinate, ascorbate, gluconate, fumarate and salicylate.
  • ferrous ion for example, as ferrous sulphate or other salts such as, in particular, aspartate, citrate, picolinate, ascorbate, gluconate, fumarate and salicylate.
  • composition according to the invention may also comprise active ingredients selected from eicosapentaenoic acid (EPA) docahexanoic acid (DHA), ⁇ -linolenic acid, and mixtures thereof.
  • active ingredients selected from eicosapentaenoic acid (EPA) docahexanoic acid (DHA), ⁇ -linolenic acid, and mixtures thereof.
  • EPA eicosapentaenoic acid
  • DHA docahexanoic acid
  • ⁇ -linolenic acid eicosapentaenoic acid
  • active ingredients selected from eicosapentaenoic acid (EPA) docahexanoic acid (DHA), ⁇ -linolenic acid, and mixtures thereof.
  • EPA eicosapentaenoic acid
  • DHA docahexanoic acid
  • ⁇ -linolenic acid eicosapentaenoic acid
  • composition according to the invention is formulated in a form suitable for oral administration, in particular as soft-shell or rigid-shell gelatine capsules, tablets, pills, elixirs, suspensions, and syrups.
  • composition in promoting iron absorption has been confirmed by clinical tests on twenty female patients with levels of sideraemia below the threshold value.
  • capsules each of 800 mg were administered to the twenty patients under test for thirty days; the capsules comprised:
  • shark cartilage extract 300 mg/cps
  • folic acid 50 ⁇ g/cps
  • vitamin E 15 mg/cps
  • borage oil 240 mg/cps.
  • the twenty patients under test had sideraemia values greatly above the threshold value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Use of a composition comprising cartilage or chondroitin sulphate and absorbable zinc for the preparation of a food supplement or a drug suitable for promoting iron absorption in patients suffering from lack of iron.

Description

  • The present invention relates to a food-supplement or pharmaceutical composition suitable for promoting iron absorption and to the treatment of anaemia conditions caused by lack of iron.
  • Lack of iron due to diets which are poor in iron or to low iron absorption by the organism is one of the primary causes of anaemia. Its therapeutic treatment is based on the administration of iron supplements such as, in particular, ferrous sulphate, with prolonged treatment required to re-establish the organism's iron reserves.
  • Prolonged administration of ferrous sulphate which constitutes the standard drug of reference, however, causes side effects such as gastrointestinal disorders, gastric irritation, cramps and diarrhoea which—when they arise—require a substantial reduction of the dosages.
  • The main problem is due to the low rate of iron absorption by the organism, which is of the order of approximately only 5-15% of the iron administered. For this reason, research relating to anti-anaemic agents for the treatment of anaemia caused by iron deficiency have been directed mainly towards the identification of preparations which can improve the solubility of iron with the use of pharmaceutical additives which improve its solubility by forming complex salts with iron, and agents such as reducing agents which can prevent oxidation of ferrous iron to ferric iron.
  • The present invention is based on the discovery of the fact that iron absorption can be increased by the administration of a composition comprising cartilage and absorbable zinc.
  • The subject of the invention is therefore the use of a composition comprising cartilage and absorbable zinc for the preparation of a food supplement or a drug which is suitable for increasing iron absorption in an individual suffering from a lack of that element and is suitable for the treatment of anaemia conditions caused by lack of iron.
  • In particular, the above-mentioned composition has been found suitable for promoting the absorption both of iron which is naturally present in foods and of iron which is administered—generally as a ferrous salt or complex—as a supplement in diets that are poor in iron or as a drug in the treatment of anaemia caused by lack of iron.
  • The cartilage which is used within the scope of the invention is generally an extract of fish cartilage, in particular cartilage of sharks or other large fish such as rays, comprising—as active ingredient—chondroitin sulphate, that is, a mixture of acid mucopolysaccharides formed by a repeating linear unit containing several sulphate groups. The basic units are constituted by N-acetyl-galactosamine and by glucuronic acid.
  • The use of preparations based on mucopolysaccharides or chondroitin sulphate and its salts, for example, such as sodium or potassium salts, is intended to be included within the scope of the invention.
  • Standardized extracts of shark cartilage are available commercially and their anti-angiogenic, anti-tumour, and anti-inflammatory activity and activity in improving skin and cartilage nutrition are already known.
  • The absorbable zinc is present in the composition in the form of salts with various counter-ions such as, for example, citrate, aspartate, pidolate, orotate, fumarate, gluconate, lactate, malate, succinate, picolinate, α-ketoglutarate, or mixtures thereof.
  • A form of zinc administration may be so-called Krebs zinc which is constituted by salified zinc with a mixture of anions formed by five primary organic acids of the Krebs cycle, that is, a mixture of zinc salts of citric, fumaric, malic, α-ketoglutaric, and succinic acids.
  • The cartilage extract. and the zinc may be administered, according to the invention, within the following range of dosages:
  • cartilage extract: 10-2000 mg/day
  • zinc (expressed as the ion): 5-100 mg/day.
  • The composition may also comprise a haematopoietic agent with anti-anaemic properties such as, in particular, folic acid, cyanocobalamin (vitamin B12) and pyridoxine (vitamin B6) and mixtures thereof with daily doses of the order of from 60 to 2000 μg/day.
  • In the preferred embodiment, the composition also comprises at least one anti-oxidizing agent or preferably a mixture of antioxidants which preferably comprise hydrophilic antioxidants and hydrophobic antioxidants.
  • The above-mentioned anti-oxidizing agents comprise:
  • vitamin C, typically administered in quantities of from 50 to 1000 mg/day,
  • vitamin E, typically administered in quantities of from 5 to 500 mg/day, and
  • bioflavonoids, containing proanthocyanidin and terpene compounds.
  • The preferred sources of bioflavonoids or of terpene compounds in the composition of the invention comprise natural extracts such as, in particular:
  • extract of Vitis vinifera (containing leucocyanidin or leucoanthocyanin), comprising procyanidolic oligomers, typically dimers, trimers, tetramers, pentamers and heptamers produced by condensation of monomeric units of flavan-3-ols and flavan-3,4-diols, free or esterified with gallic acid;
  • extract of Centella asiatica obtained by extraction and purification of the aerial part of Centella asiatica (asiatic hydrocotyl), typically comprising a terpenic mixture of madecassic acid (about 30%), asiatic acid (about 30%) and asiaticoside (about 40%);
  • standardized extract of Ginkgo biloba comprising bioflavones, flavonolglucosides and lactonic terpenes.
  • The above-mentioned extracts may be used in association in the composition according to the invention and may optionally be standardized extracts in complexed form with phospholipids to improve bio-availability.
  • Typical dosages of these extracts in the composition of the invention are of the order of from 10 to 500 mg/day.
  • Further anti-oxidizing agents that may be used comprise lipoic acid and lycopene.
  • The presence of the above-mentioned anti-oxidizing agents—and particularly of the bioflavonoid-based antioxidants—may be considered synergic in increasing iron absorption by favouring the presence of reduced iron which is that which is most easily absorbed.
  • The invention includes within its scope both iron-free compositions and compositions including iron—generally as ferrous ion—the combined use of which is rendered necessary when the lack of iron in the patient undergoing treatment is also due to a diet that is poor in iron. It is intended that the administration of iron supplements may be performed in association with the composition according to the invention or in combined treatment.
  • If the administration of iron is associated with the composition according to the invention, the composition may typically comprise doses of the order of from 5 to 300 mg/day of iron, as the ferrous ion, for example, as ferrous sulphate or other salts such as, in particular, aspartate, citrate, picolinate, ascorbate, gluconate, fumarate and salicylate.
  • The composition according to the invention may also comprise active ingredients selected from eicosapentaenoic acid (EPA) docahexanoic acid (DHA), γ-linolenic acid, and mixtures thereof. As the source of eicosapentaenoic acid and docahexanoic acid, the use of fish oil or microalgae oil is preferable and, as the source of γ-linolenic acid, the use of borage oil or evening primrose oil is preferred.
  • The composition according to the invention is formulated in a form suitable for oral administration, in particular as soft-shell or rigid-shell gelatine capsules, tablets, pills, elixirs, suspensions, and syrups.
  • The activity of the composition in promoting iron absorption has been confirmed by clinical tests on twenty female patients with levels of sideraemia below the threshold value.
  • Four capsules each of 800 mg were administered to the twenty patients under test for thirty days; the capsules comprised:
  • shark cartilage extract: 300 mg/cps
  • zinc (expressed as the ion): 7.5 mg/cps
  • folic acid: 50 μg/cps
  • extract of Centella asiatica: 20 mg/cps
  • extract of leucocyanidin (Vitis vinifera): 50 mg/cps
  • vitamin E: 15 mg/cps
  • fish oil: 120 mg/cps
  • borage oil: 240 mg/cps.
  • During the period of treatment the patients were required to maintain a normal diet which was confirmed not to be lacking in iron.
  • Upon completion of the treatment, the twenty patients under test had sideraemia values greatly above the threshold value.
  • The following table gives the sideraemia values as mean initial values, final values and normal values.
    Mean initial Mean final
    values values Normal values
    Sideraemia 38 mcg/dl 75 mcg/dl 50-160 mcg/dl

Claims (13)

1. A method for preparing an iron absorption composition which comprises mixing: (a) cartilage or chondroitin sulphate and (b) absorbable zinc in concentrations suitable for promoting iron absorption in patients suffering from lack of iron.
2. A method according to claim 13 for treating patients suffering from anaemia caused by lack of iron.
3. A method according to claim 13 in which said composition comprises cartilage and zinc, and said composition is administered at a rate sufficient to provide a cartilage administration rate within the range of from 100 to 2000 mg/day and the zinc, expressed as the ion, is administered at a rate of from 5 to 100 mg/day.
4. A method according to claim 1 in which the cartilage is a standardized shark cartilage extract.
5. A method according to claim 13 in which the absorbable zinc in said composition is administered in the form of a salt selected from the group consisting of citrate, fumarate, gluconate, α-ketoglutarate, lactate, malate, succinate, picolinate, aspartate, pidolate, orotate, and mixtures thereof.
6. A method according to claim 1 in which the composition further comprises a haematopoietic agent selected from folic acid, vitamin B6 and vitamin B12.
7. A method according to claim 6 in which the haematopoietic agent is included in the composition for administration within the range of from 60 to 2000 μg/day.
8. A method according to claim 1 in which the composition further comprises at least one anti-oxidizing agent selected from the group which consists of vitamin E, vitamin C, bioflavonoids, terpenes, lycopene, lipoic acid, and mixtures thereof.
9. A method according to claim 8 in which the bioflavonoid-based anti-oxidizing agent comprises a vegetable extract selected from extract of Vitis vinifera, extract of Ginkgo biloba, extract of Centella asiatica, and mixtures thereof.
10. A method according to claim 1 in which the composition further comprises an iron salt.
11. A method according to claim 10 in which the iron salt is present in an amount sufficient to provide an administered dose of from 5 to 300 mg/day (expressed as the ferrous ion).
12. A method according to claim 13 further comprising combined therapy with drugs or iron supplements.
13. A method for enhancing iron absorption in a patient suffering from lack of iron by administering to said patient an effective amount of a composition comprising: (a) cartilage or chondroitin sulphate, and (b) absorbable zinc, each being present in a concentration suitable for promoting iron absorption in treated patients.
US10/546,247 2003-02-20 2004-02-18 Food-supplement composition suitable for promoting iron absorption Abandoned US20060177516A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/034,046 US8119167B2 (en) 2003-02-20 2008-02-20 Food supplement composition suitable for promoting iron absorption

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000126A ITTO20030126A1 (en) 2003-02-20 2003-02-20 COMPOSITION OF FOOD SUPPLEMENT SUITABLE TO FAVOR THE ABSORPTION OF IRON.
ITTO2003A000126 2003-02-20
PCT/EP2004/001526 WO2004073721A1 (en) 2003-02-20 2004-02-18 A food-supplement composition suitable for promoting iron absorption

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/034,046 Division US8119167B2 (en) 2003-02-20 2008-02-20 Food supplement composition suitable for promoting iron absorption

Publications (1)

Publication Number Publication Date
US20060177516A1 true US20060177516A1 (en) 2006-08-10

Family

ID=32894190

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/546,247 Abandoned US20060177516A1 (en) 2003-02-20 2004-02-18 Food-supplement composition suitable for promoting iron absorption
US12/034,046 Expired - Fee Related US8119167B2 (en) 2003-02-20 2008-02-20 Food supplement composition suitable for promoting iron absorption

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/034,046 Expired - Fee Related US8119167B2 (en) 2003-02-20 2008-02-20 Food supplement composition suitable for promoting iron absorption

Country Status (8)

Country Link
US (2) US20060177516A1 (en)
EP (1) EP1605954B1 (en)
AT (1) ATE407682T1 (en)
DE (1) DE602004016472D1 (en)
ES (1) ES2314376T3 (en)
IT (1) ITTO20030126A1 (en)
RU (1) RU2340370C2 (en)
WO (1) WO2004073721A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154966A1 (en) 2010-06-10 2011-12-15 Indus Biotech Pvt. Ltd. A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
US20160309764A1 (en) * 2013-12-16 2016-10-27 Nestec S.A. Food composition comprising ferrous picolinate

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2314118C1 (en) * 2006-08-08 2008-01-10 Майя Отаровна Везиришвили Method for preparing extracts possessing antioxidant activity from cultivated grape compound fruit racemes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031744A1 (en) * 1997-02-04 2001-10-18 Kosbab John V. Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
US20030118666A1 (en) * 2001-10-12 2003-06-26 Seiji Nishida Injectable solution containing a shark-derived chondroitin sulfate iron colloid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021811C1 (en) * 1992-09-01 1994-10-30 Васюков Сергей Ефимович Agent for joint disease treatment showing antiinflammatory and analgesic effect

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031744A1 (en) * 1997-02-04 2001-10-18 Kosbab John V. Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
US20030118666A1 (en) * 2001-10-12 2003-06-26 Seiji Nishida Injectable solution containing a shark-derived chondroitin sulfate iron colloid

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154966A1 (en) 2010-06-10 2011-12-15 Indus Biotech Pvt. Ltd. A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof
US9139608B2 (en) 2010-06-10 2015-09-22 Indus Biotech Private Limited Method for preparation of highly pure asiaticoside composition from Centella asiatica and a method of use thereof
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
US20160309764A1 (en) * 2013-12-16 2016-10-27 Nestec S.A. Food composition comprising ferrous picolinate
US20160374370A1 (en) * 2013-12-16 2016-12-29 Nestec S.A. Beverage comprising ferrous picolinate

Also Published As

Publication number Publication date
EP1605954A1 (en) 2005-12-21
EP1605954B1 (en) 2008-09-10
RU2340370C2 (en) 2008-12-10
WO2004073721A1 (en) 2004-09-02
ES2314376T3 (en) 2009-03-16
ITTO20030126A1 (en) 2004-08-21
US8119167B2 (en) 2012-02-21
ATE407682T1 (en) 2008-09-15
US20080138436A1 (en) 2008-06-12
RU2005129261A (en) 2006-03-10
DE602004016472D1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
EP0514451B1 (en) Dietary supplements comprising vitamins and minerals
US20070292493A1 (en) Pharmaceutical composition and method for the transdermal delivery of calcium
US6451341B1 (en) Time release formulation of vitamins, minerals and other beneficial supplements
EP1978949B1 (en) Combination preparation for improving sperm quality
US8119167B2 (en) Food supplement composition suitable for promoting iron absorption
WO2007108712A1 (en) Kit and method for treating or preventing anemia caused by iron deficiency
KR101262293B1 (en) Method of Manufacturing Stable and High Concentration Calcium Phosphate Aqueous Solutions in Neutral pH Range
US20060210650A1 (en) Supplemental dietary composition for promoting weight loss
US6461650B1 (en) Preparation for supplementing a beverage and method for enriching a beverage in calcium and magnesium
DE3936319C2 (en)
KR20100008400A (en) The composition for the atopic dermatitis improving with vinegar
US7998500B2 (en) Nutritional supplement for women
RU2765266C1 (en) Composition for the production of natural lollipops
EP3693020A1 (en) Potassium enriched topical formulations for pain relief and sleep aid
Namitha Jayapal et al. ROLE OF ZINC IN ORAL HEALTH: A REVIEW
CN101375913B (en) Pharmaceutical combination for preventing birth-defect and improving memory
CN101455698B (en) Medicine composition for prenatal and postnatal care and preventing the birth defect and improving the memory
CN101396501A (en) Medicine composition for preventing the birth defect and improving the memory
CA2074527A1 (en) Dietary supplements comprising vitamins and minerals
CN101396408A (en) Medicine composition for prenatal and postnatal care and preventing the birth defect and improving the memory
CN101375941A (en) Pharmaceutical combination for preventing birth-defect and improving memory
CN101375911A (en) Pharmaceutical combination for preventing birth-defect and improving memory
CN101264101A (en) Medicinal composition for preventing birth defect and improving memory in prepotency
CN101396409A (en) Medicine composition for prenatal and postnatal care and preventing the birth defect and improving the memory
CN101396502A (en) Medicine composition for preventing the birth defect and improving the memory

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDESTEA RESERACH AND PRODUCTION S.R.L., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MERIZZI, GIANFRANCO;REEL/FRAME:017688/0705

Effective date: 20050728

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION